Literature DB >> 16679521

The TACE zymogen: re-examining the role of the cysteine switch.

Marcos E Milla1, Patricia E Gonzales, Jennifer D Leonard.   

Abstract

The tumor necrosis factor-alpha-converting enzyme (TACE) is a member of the disintegrin family of metalloproteinases (ADAMs) that plays a central role in the regulated shedding of a host of cell surface proteins. TACE is biosynthesized as a precursor protein with latent proteolytic activity (zymogen). TACE's zymogen inhibition is mediated by its Pro domain, a 197-amino acid region that serves this function as well as aiding in the secretion of this enzyme through the secretory pathway. We have discovered that a conserved "cysteine switch" consensus motif within TACE's Pro domain is, contrary to expectations, not required for maintenance of the inactive precursor state or for the secretion of this metalloproteinase in its functional form. The only role for this motif seems to be in decreasing TACE's susceptibility to proteolytic degradation during its biogenesis and maturation within the secretory pathway. Interestingly, the Pro domain of TACE seems to carry both its inhibitory and secretory functions through the same mechanism: it seems to prevent the Catalytic domain from accessing its native, functional state, resembling the function of true molecular chaperones. Recent evidence suggests that TACE may also be switched out of the active conformation even by small, drug-like molecules such as the synthetic compound SB-3CT. These findings point at the possibility of developing, in the near future, a new generation of antiinflammatory, noncompetitive TACE inhibitors that would exert negative allosteric modulation over the activity of this key enzyme, mediating several inflammatory diseases and certain cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679521     DOI: 10.1385/CBB:44:3:342

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  8 in total

Review 1.  Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-alpha-converting enzyme.

Authors:  Irit Sagi; Marcos E Milla
Journal:  Anal Biochem       Date:  2007-09-26       Impact factor: 3.365

Review 2.  Molecular mechanisms of soluble cytokine receptor generation.

Authors:  Stewart J Levine
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

Review 3.  The history of matrix metalloproteinases: milestones, myths, and misperceptions.

Authors:  Rugmani Padmanabhan Iyer; Nicolle L Patterson; Gregg B Fields; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-17       Impact factor: 4.733

4.  Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.

Authors:  Mallory Gough; Catherine Parr-Sturgess; Edward Parkin
Journal:  Biochem Res Int       Date:  2010-09-30

5.  ATP-mediated activation of the NADPH oxidase DUOX1 mediates airway epithelial responses to bacterial stimuli.

Authors:  Agnes W Boots; Milena Hristova; David I Kasahara; Guido R M M Haenen; Aalt Bast; Albert van der Vliet
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

6.  Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo.

Authors:  Eitan Wong; Tal Cohen; Erez Romi; Maxim Levin; Yoav Peleg; Uri Arad; Avraham Yaron; Marcos E Milla; Irit Sagi
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

7.  Specific inhibition of ADAM17/TACE promotes neurogenesis in the injured motor cortex.

Authors:  Noelia Geribaldi-Doldán; Manuel Carrasco; Maribel Murillo-Carretero; Samuel Domínguez-García; Francisco J García-Cózar; Juan Pedro Muñoz-Miranda; Valme Del Río-García; Cristina Verástegui; Carmen Castro
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

Review 8.  The ADAM metalloproteinases.

Authors:  Dylan R Edwards; Madeleine M Handsley; Caroline J Pennington
Journal:  Mol Aspects Med       Date:  2008-08-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.